Otezla Is Amgen’s Main Growth Driver As Net Drug Pricing Declines
Executive Summary
Without the newly purchased drug, Amgen’s 2020 sales would be flat, but the company hopes to enhance its psoriasis market push with its combined offering of Otezla, Enbrel and biosimilars.
You may also be interested in...
Amgen Optimistic About 2020 Despite COVID-19 Impacts
Relatively upbeat during the company’s Q1 call based on Amgen’s product mix, executives expect the biggest coronavirus-related sales impacts in Q2 with stabilization and growth in the second half.
A Rocky First Quarter For Big Pharma Stocks
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
Amgen Gets US Infliximab Nod
Amgen has received its fourth US biosimilar approval for its Avsola infliximab rival to Janssen’s Remicade.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports